The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unc ...

Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates remain hig ...

Integrating ICI earlier in the treatment sequence through total neoadjuvant therapy may enhance the immune response against the primary tumor and the hidden metastases and potentially lead to improved ...

The addition of olaparib to neoadjuvant chemotherapy improved overall survival in BRCA -mutated breast cancer, despite no improvement in pathologic response. Adding the PARP inhibitor led to a 3 ...

Neoadjuvant mitomycin C showed a favorable safety profile with mild to moderate side effects, including hematuria, dysuria, and itchy scalp. The trial did not show significant improvement in 12-month ...

PD-1 immunotherapy can eliminate the need for surgery in patients with early-stage, DNA mismatch repair-deficient solid cancers, according to results presented by Andrea Cercek, MD, at the AACR ...

Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Omission of Radiotherapy or Not? The following represents disclosure information provided by authors of this manuscript. All relationships are ...

HealthDay News — Omission of breast surgery after neoadjuvant systemic therapy (NST) in select patients with invasive breast cancer may be feasible, according to a study published online March ...

Neoadjuvant chemotherapy is chemotherapy that's given before your primary treatment. Learn when it's used, course of treatment, benefits, and effectiveness.

As part of non-platinum neoadjuvant therapy for muscle-invasive bladder cancer, TAR-200 did not worsen perioperative morbidity or mortality.

The research team first evaluated the clinical characteristics and response to the neoadjuvant regimen and assigned an appropriate “response-adapted locoregional therapy” involving standard treatments ...

Neoadjuvant Chemoradiation Plus Immunotherapy Boosts Responses in Esophageal Cancer — Phase III trial suggests regimen "has the potential to become the new standard of care" ...